The stock of SCYNEXIS Inc (NASDAQ:SCYX) is a huge mover today! About 523,271 shares traded hands. SCYNEXIS Inc (NASDAQ:SCYX) has declined 2.60% since March 2, 2016 and is downtrending. It has underperformed by 10.86% the S&P500.
The move comes after 9 months positive chart setup for the $112.81 million company. It was reported on Oct, 5 by Barchart.com. We have $13.91 PT which if reached, will make NASDAQ:SCYX worth $208.70 million more.
Analysts await SCYNEXIS Inc (NASDAQ:SCYX) to report earnings on November, 11.
SCYNEXIS Inc (NASDAQ:SCYX) Ratings Coverage
Out of 5 analysts covering Scynexis Inc (NASDAQ:SCYX), 5 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Scynexis Inc has been the topic of 7 analyst reports since August 20, 2015 according to StockzIntelligence Inc. The firm has “Outperform” rating by RBC Capital Markets given on Monday, November 16. The stock has “Buy” rating given by Needham on Thursday, August 20. As per Monday, October 3, the company rating was initiated by Brean Capital. The stock of SCYNEXIS Inc (NASDAQ:SCYX) earned “Strong Buy” rating by WBB Securities on Tuesday, December 29. The firm earned “Buy” rating on Wednesday, August 17 by Guggenheim. The rating was initiated by Brean Capital on Monday, March 28 with “Buy”. The rating was upgraded by WBB Securities on Tuesday, August 9 to “Buy”.
According to Zacks Investment Research, “SCYNEXIS, Inc. is a pharmaceutical company. It is engaged in the discovery, development, and commercialization of anti-infectives to address unmet therapeutic needs. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. It also provides contract research and development services. SCYNEXIS, Inc. is headquartered in Durham, North Carolina.”
Insitutional Activity: The institutional sentiment increased to 1.82 in Q2 2016. Its up 0.02, from 1.8 in 2016Q1. The ratio is positive, as 4 funds sold all SCYNEXIS Inc shares owned while 7 reduced positions. 10 funds bought stakes while 10 increased positions. They now own 13.69 million shares or 61.88% more from 8.46 million shares in 2016Q1.
Morgan Stanley accumulated 0% or 9,320 shares. Moreover, Ubs Oconnor Limited Liability Company has 0% invested in SCYNEXIS Inc (NASDAQ:SCYX) for 250,000 shares. The New Jersey-based Jacobs Levy Equity Mngmt Inc has invested 0% in SCYNEXIS Inc (NASDAQ:SCYX). The New Jersey-based Private Advisor Grp Inc Ltd Com has invested 0.02% in SCYNEXIS Inc (NASDAQ:SCYX). Fmr Ltd holds 1.73 million shares or 0% of its portfolio. Deerfield Mgmt has invested 0.15% of its portfolio in SCYNEXIS Inc (NASDAQ:SCYX). Awm Inc holds 0.06% of its portfolio in SCYNEXIS Inc (NASDAQ:SCYX) for 125,000 shares. Sphera Funds Ltd, a Israel-based fund reported 128,500 shares. Geode Capital Mngmt Lc owns 55,168 shares or 0% of their US portfolio. Ladenburg Thalmann Fincl Svcs last reported 3,156 shares in the company. Granite Point Capital Mgmt Lp last reported 175,000 shares in the company. Armistice Llc, a New York-based fund reported 698,000 shares. Iguana Health Mngmt Limited Co accumulated 0.11% or 125,000 shares. Blackrock Fund Advsr, a California-based fund reported 30,090 shares. Sabby Ltd Limited Liability Company has 572,928 shares for 0.06% of their US portfolio.
Insider Transactions: Since May 19, 2016, the stock had 7 insider purchases, and 0 selling transactions for $276,683 net activity. Angulo Gonzalez David bought $82,159 worth of stock or 36,950 shares. On Thursday, May 19 the insider Taglietti Marco bought $18,420. HANHAM ANN bought $15,379 worth of stock. The insider Machado Patrick bought 40,000 shares worth $117,600.
More news for SCYNEXIS Inc (NASDAQ:SCYX) were recently published by: Globenewswire.com, which released: “SCYNEXIS, Inc. Receives Orphan Drug Designation for SCY-078 for the Treatment …” on August 24, 2016. Finance.Yahoo.com‘s article titled: “SCYNEXIS, Inc. to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference” and published on July 06, 2016 is yet another important article.
SCYX Company Profile
SCYNEXIS, Inc., incorporated on November 4, 1999, is a pharmaceutical company, which is engaged in the discovery, development and commercialization of anti-infectives to address unmet therapeutic needs. The Firm is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains. It also conducts additional in vitro and in vivo studies to further characterize the spectrum of activity of SCY-078. Candida and Aspergillus species are the fungi responsible for all invasive fungal infections in the United States and Europe. The Firm has completed multiple Phase I studies with the oral formulation of SCY-078 and is conducting its first Phase I study with the IV formulation of SCY-078.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.